Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
How did PANC's recent EPS compare to expectations?
The most recent EPS for Panacos Pharmaceuticals Inc is $, expectations of $.
How did Panacos Pharmaceuticals Inc PANC's revenue perform in the last quarter?
Panacos Pharmaceuticals Inc revenue for the last quarter is $
What is the revenue estimate for Panacos Pharmaceuticals Inc?
According to of Wall street analyst, the revenue estimate of Panacos Pharmaceuticals Inc range from $ to $
What's the earning quality score for Panacos Pharmaceuticals Inc?
Panacos Pharmaceuticals Inc has a earning quality score of B-/24.80611. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Panacos Pharmaceuticals Inc report earnings?
Panacos Pharmaceuticals Inc next earnings report is expected in
What are Panacos Pharmaceuticals Inc's expected earnings?
Panacos Pharmaceuticals Inc expected earnings is $, according to wall-street analysts.
Did Panacos Pharmaceuticals Inc beat earnings expectations?
Panacos Pharmaceuticals Inc recent earnings of $ expectations.